The DESTINY-Lung01 trial enrolled patients with HER2-positive pretreated metastatic non-small cell lung cancer, while the DESTINY-CRC02 trial enrolled patients with HER2-positive metastatic colorectal cancer refractory to prior standard therapy or for whom prior therapy was contraindicated. Here, ERBB2 is linked to non-small cell lung carcinoma.